ArticlePlacenta2026
Characterizing placental dysfunction with DNA methylation profiling and placental histopathology.
Article in Placenta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DNA methylation in the placenta and household socioeconomic status: the SPAH study.Clinical epigenetics · 2026Article
- A placental DNA methylation score associated with early-onset preeclampsia and maternal vascular malperfusion pathology.Frontiers in epigenetics and epigenomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPlacental pathology is associated with abnormal fetal growth and development. Altered placental DNA methylation (DNAme) has been associated with preeclampsia and fetal growth restriction but has not been well studied in the context of placental pathology, which likely underlies such changes. Our goal was thus to evaluate the association of DNAme with four major classes of placental pathology.
methodsWe utilized data from 484 placentas with both Illumina EPICv1 DNAme data and detailed histopathology information. Placental lesions were grouped as: acute inflammation (AI), chronic inflammation (CI), maternal vascular malperfusion (MVM), and fetal vascular malperfusion (FVM). We evaluated associations with DNAme based estimates of placental cell-types and epigenetic age acceleration, and used linear models to explore changes to autosome-wide DNAme with pathology.
resultsWe identified 281 and 56 CpGs that were differentially methylated (FDR<0.05, |Δβ|>0.05) in association with high-grade MVM and high-grade FVM respectively. High-grade MVM and high-grade FVM were associated with increased and decreased estimates of syncytiotrophoblast respectively. There were no CpGs differentially methylated in association with the inflammation pathologies. Epigenetic age acceleration was not associated with any pathology, suggesting the placental epigenetic clocks are robust at estimating gestational age in the presence of pathology.
conclusionsChanges in DNAme were associated with high-grade vascular pathologies, and DNAme may complement histopathologic placental examination. While changes largely reflected altered cell composition, altered gene regulation at the cellular level may also be present in these pathologies. Differential DNAme in high-grade MVM/FVM may contribute to or be a response to placental pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.